메뉴 건너뛰기




Volumn 52, Issue 9, 2008, Pages 3276-3283

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors

(15)  Robbins, Brian L a   Capparelli, Edmund V b   Chadwick, Ellen G c   Yogev, Ram c   Serchuck, Leslie d,m   Worrell, Carol d   Smith, Mary Elizabeth d,e   Alvero, Carmelita f   Fenton, Terence f   Heckman, Barbara g   Pelton, Stephen I h   Aldrovandi, Grace i   Borkowsky, William j   Rodman, John a   Havens, Peter L k,l  


Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

EID: 50949107933     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00224-08     Document Type: Article
Times cited : (24)

References (40)
  • 1
    • 26944437399 scopus 로고    scopus 로고
    • Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, D. Burger, and H.-N. S. Team. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
    • Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, D. Burger, and H.-N. S. Team. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
  • 2
    • 33748170155 scopus 로고    scopus 로고
    • An update on therapeutic drug monitoring for antiretroviral drugs
    • Back, D., S. Gibbons, and S. Khoo. 2006. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28:468-473.
    • (2006) Ther. Drug Monit , vol.28 , pp. 468-473
    • Back, D.1    Gibbons, S.2    Khoo, S.3
  • 6
    • 18744374174 scopus 로고    scopus 로고
    • A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients
    • Dailly, E., V. Reliquet, F. Raffi, and P. Jolliet. 2005. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 61:153-156.
    • (2005) Eur. J. Clin. Pharmacol , vol.61 , pp. 153-156
    • Dailly, E.1    Reliquet, V.2    Raffi, F.3    Jolliet, P.4
  • 8
    • 0141612910 scopus 로고    scopus 로고
    • Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. D. Lundgren, and MaxCmin1 Trial Group. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
    • Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. D. Lundgren, and MaxCmin1 Trial Group. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
  • 9
    • 0019368150 scopus 로고
    • The inhibitory quotient. A method for interpreting minimum inhibitory concentration data
    • Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
    • (1981) JAMA , vol.246 , pp. 1575-1578
    • Ellner, P.D.1    Neu, H.C.2
  • 11
    • 33750546218 scopus 로고    scopus 로고
    • Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment- experienced HIV-infected patients receiving lopinavir/ritonavir
    • Gianotti, N., L. Galli, A. Danise, H. Hasson, E. Boeri, A. Lazzarin, and A. Castagna. 2006. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment- experienced HIV-infected patients receiving lopinavir/ritonavir. J. Med. Virol. 78:1537-1541.
    • (2006) J. Med. Virol , vol.78 , pp. 1537-1541
    • Gianotti, N.1    Galli, L.2    Danise, A.3    Hasson, H.4    Boeri, E.5    Lazzarin, A.6    Castagna, A.7
  • 15
    • 12244262297 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
    • Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
    • (2003) Antimicrob. Agents Chemother , vol.47 , pp. 350-359
    • Hsu, A.1    Isaacson, J.2    Brun, S.3    Bernstein, B.4    Lam, W.5    Bertz, R.6    Foit, C.7    Rynkiewicz, K.8    Richards, B.9    King, M.10    Rode, R.11    Kempf, D.J.12    Granneman, G.R.13    Sun, E.14
  • 18
    • 34848893678 scopus 로고    scopus 로고
    • Justesen, U. S., Z. Fox, C. Pedersen, P. Cahn, J. Gerstoft, N. Clumeck, M. Losso, B. Peters, N. Obel, A. Castagna, U. B. Dragsted, J. D. Lundgren, and MaxCmin Trial Group. 2007. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin. Pharmacol. Toxicol. 101:339-344.
    • Justesen, U. S., Z. Fox, C. Pedersen, P. Cahn, J. Gerstoft, N. Clumeck, M. Losso, B. Peters, N. Obel, A. Castagna, U. B. Dragsted, J. D. Lundgren, and MaxCmin Trial Group. 2007. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin. Pharmacol. Toxicol. 101:339-344.
  • 19
    • 0037032931 scopus 로고    scopus 로고
    • Diurnal variation of plasma protease inhibitor concentrations
    • Justesen, U. S., and C. Pedersen. 2002. Diurnal variation of plasma protease inhibitor concentrations. AIDS 16:2487-2489.
    • (2002) AIDS , vol.16 , pp. 2487-2489
    • Justesen, U.S.1    Pedersen, C.2
  • 20
    • 0036768328 scopus 로고    scopus 로고
    • Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy
    • Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
    • (2002) Antivir. Ther , vol.7 , pp. 165-174
    • Kempf, D.J.1    Isaacson, J.D.2    King, M.S.3    Brun, S.C.4    Sylte, J.5    Richards, B.6    Bernstein, B.7    Rode, R.8    Sun, E.9
  • 21
    • 34147176581 scopus 로고    scopus 로고
    • The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
    • Klein, C. E., Y.-L. Chiu, W. Awni, T. Zhu, R. S. Heuser, T. Doan, J. Breitenbach, J. B. Morris, S. C. Brun, and G. J. Hanna. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410.
    • (2007) J. Acquir. Immune Defic. Syndr , vol.44 , pp. 401-410
    • Klein, C.E.1    Chiu, Y.-L.2    Awni, W.3    Zhu, T.4    Heuser, R.S.5    Doan, T.6    Breitenbach, J.7    Morris, J.B.8    Brun, S.C.9    Hanna, G.J.10
  • 23
    • 0042628231 scopus 로고    scopus 로고
    • Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy
    • la Porte, C. J., J. C. Wasmuth, K. Schneider, J. K. Rockstroh, and D. M. Burger. 2003. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 17:1700-1702.
    • (2003) AIDS , vol.17 , pp. 1700-1702
    • la Porte, C.J.1    Wasmuth, J.C.2    Schneider, K.3    Rockstroh, J.K.4    Burger, D.M.5
  • 24
    • 33846117422 scopus 로고    scopus 로고
    • The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    • Maillard, A., J.-M. Chapplain, O. Tribut, D. Bentue-Ferrer, P. Tattevin, C. Arvieux, C. Michelet, and A. Ruffault. 2007. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J. Clin. Virol. 38:131-138.
    • (2007) J. Clin. Virol , vol.38 , pp. 131-138
    • Maillard, A.1    Chapplain, J.-M.2    Tribut, O.3    Bentue-Ferrer, D.4    Tattevin, P.5    Arvieux, C.6    Michelet, C.7    Ruffault, A.8
  • 27
    • 33645096370 scopus 로고    scopus 로고
    • Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy
    • Morse, G. D., L. M. Catanzaro, and E. P. Acosta. 2006. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6:215-225.
    • (2006) Lancet Infect. Dis , vol.6 , pp. 215-225
    • Morse, G.D.1    Catanzaro, L.M.2    Acosta, E.P.3
  • 30
    • 26944478140 scopus 로고    scopus 로고
    • Ramos, J. T., M. I. De Jose, J. Duenas, C. Fortuny, R. Gonzalez-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Munoz-Fernandez, and E. Cabrero on behalf of the Spanish Collaborative Group on HIV Infection in Children. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
    • Ramos, J. T., M. I. De Jose, J. Duenas, C. Fortuny, R. Gonzalez-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Munoz-Fernandez, and E. Cabrero on behalf of the Spanish Collaborative Group on HIV Infection in Children. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
  • 31
    • 32644444845 scopus 로고    scopus 로고
    • Resino, S., J. M. Bellon, and M. A. Munoz-Fernandez on behalf of the Spanish Group of HIV Infection. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
    • Resino, S., J. M. Bellon, and M. A. Munoz-Fernandez on behalf of the Spanish Group of HIV Infection. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
  • 34
    • 7244243920 scopus 로고    scopus 로고
    • Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    • Ribera, E., R. M. Lopez, M. Diaz, L. Pou, L. Ruiz, V. Falco, M. Crespo, C. Azuaje, I. Ruiz, I. Ocana, B. Clotet, and A. Pahissa. 2004. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4256-4262.
    • (2004) Antimicrob. Agents Chemother , vol.48 , pp. 4256-4262
    • Ribera, E.1    Lopez, R.M.2    Diaz, M.3    Pou, L.4    Ruiz, L.5    Falco, V.6    Crespo, M.7    Azuaje, C.8    Ruiz, I.9    Ocana, I.10    Clotet, B.11    Pahissa, A.12
  • 37
    • 34247147314 scopus 로고    scopus 로고
    • Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, and the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
    • Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, and the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
  • 40
    • 33745770427 scopus 로고    scopus 로고
    • Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children
    • van der Lee, M., G. Verweel, R. de Groot, and D. Burger. 2006. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir. Ther. 11:439-445.
    • (2006) Antivir. Ther , vol.11 , pp. 439-445
    • van der Lee, M.1    Verweel, G.2    de Groot, R.3    Burger, D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.